GKOS (Glaukos) GF Value : $85.68 (As of Apr. 27, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Glaukos GF Value?

As of today (2025-04-27), Glaukos's share price is $96.68. Glaukos's GF Value is $85.68. Therefore, Glaukos's Price-to-GF-Value for today is 1.13. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Glaukos is Modestly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Glaukos (NYSE:GKOS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (1)
Possible Value Trap, Think Twice	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (2)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (2)	Predictable High Quality Companies which are Significantly Undervalued

(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(2) A sufficient margin of safety exists only when the stock is undervalued.

Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.

Indicators that a company may be a value trap include:

    * Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
    * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
    * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.

Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.

Glaukos's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	96.68	/	85.68
	=	1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos GF Value Related Terms

Thank you for viewing the detailed overview of Glaukos's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

6GJ:Germany

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Executives

Alex R. Thurman	officer: SVP & Chief Financial Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Mark J Foley	director	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tomas Navratil	officer: Chief Development Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Gilbert H Kliman	director	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Joseph E Gilliam	officer: CFO, SVP Corporate Development	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Marc Stapley	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Thomas William Burns	director, 10 percent owner, officer: Chief Executive Officer	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Chris M. Calcaterra	officer: Chief Commercial Officer	C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan Silverstein	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison	officer: Treasurer, CFO & Secretary	26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653